Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis
Multiple Doses of AT-1501-A201 in Adults With ALS
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L).
- Trial name
- NCT04322149
- Testing
- AT-1501
- Where
- 13 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Anelixis Therapeutics, LLC
Obstructive Sleep Apnea, Amyotrophic Lateral Sclerosis
Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx
This is a pilot study to examine the diagnostic utility of a novel transmembrane surface sensor, and compare signals obtained with the transmembrane sensor to conventional needle EMG signals from healthy volunteers to those with…
- Conditions
- Obstructive Sleep Apnea, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Healthy
- Trial name
- NCT03986671
- Testing
- Transmembrane EMG Oropharynx Probe
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Powell Mansfield Inc.
Muscular Atrophy, Spinal
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
A global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).
- Trial name
- Rainbowfish (NCT03779334)
- Testing
- Risdiplam
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Amyotrophic Lateral Sclerosis
Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
The objective of this trial was to assess the efficacy, safety, and PK/PD effects of CNM-Au8 as a disease-modifying agent for the treatment of ALS by utilizing electrophysiological measures to detect preservation of motor neuron…
- Trial name
- RESCUE-ALS (NCT04098406)
- Testing
- CNM-Au8
- Where
- 2 sites in Australia
- Volunteers
- 45 people
- Sponsor
- Clene Nanomedicine
Prostate Cancer
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
This is a phase II multi-center study to determine the clinical impact of using a patient-specific genomic expression signature of androgen receptor (AR) activity to determine therapy for patients with castration-resistant…
- Trial name
- ARS (NCT00918385)
- Testing
- Nilutamide, Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Spinal Muscular Atrophy
Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
To evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2
- Trial name
- SPR1NT (NCT03505099)
- Testing
- onasemnogene abeparvovec-xioi
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 30 people
- Sponsor
- Novartis Gene Therapies
ALS (Amyotrophic Lateral Sclerosis)
Safety and Feasibility of the EyeControl Device
The EyeControl device is an eye movement-based communication device in the form of wearable glasses with connected infrared cam-era that tracks the pupil and translates blinks and movements into commands.This study is aimed to…
- Trial name
- NCT02891629
- Testing
- EyeControl device
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eyefree Assisting Communication Ltd
Amyotrophic Lateral Sclerosis (ALS)
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in…
- Trial name
- NurOwn (NCT02017912)
- Testing
- Nurown MSC-NTF cells
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brainstorm-Cell Therapeutics
Muscular Atrophy, Spinal
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
The purpose of this open-label, single arm study is to further evaluate long-term tolerability, safety and efficacy outcomes of olesoxime in participants with Spinal Muscular Atrophy (SMA) who previously participated in one of…
- Trial name
- NCT02628743
- Testing
- Olesoxime
- Where
- 24 sites in Belgium, France and 5 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Muscular Atrophy, Spinal
Progressive Strength Training in Spinal Muscular Atrophy
The proposed feasibility study is necessary to test if children and young adults will participate in and adhere to a 12-week, home-based, supervised progressive strength training exercise program and to obtain preliminary data…
- Trial name
- NCT01233817
- Testing
- Progressive strength training
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Muscular Atrophy, Spinal
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
The primary objectives of this study are to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital…
- Trial name
- DEVOTE (NCT04089566)
- Testing
- Nusinersen
- Where
- 45 sites in United States, Brazil and 16 more
- Volunteers
- 145 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)
The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis.
- Trial name
- ROSF (NCT03679975)
- Testing
- Riluzole Oral Soluble film (ROSF) 50 mg
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Aquestive Therapeutics
Amyotrophic Lateral Sclerosis
A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
This is a multi-center, open-label study of MN-166 (ibudilast) in subjects with ALS. To be eligible subjects must meet the El Escorial criteria of possible, laboratory-supported probable, probable, or definite criteria for a…
- Trial name
- NCT02714036
- Testing
- ibudilast
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- MediciNova
Castration-resistant Prostate Cancer, Metastatic Cancer
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
This trial will evaluate the use of one versus two DNA vaccines, delivered concurrently with PD-1 blockade using pembrolizumab followed by treatment with pembrolizumab alone, and delivered over a prolonged period of time (for a…
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
- Trial name
- NCT04090528
- Testing
- pTVG-HP, pTVG-AR, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional…
- Trial name
- NCT00415519
- Testing
- MCI-186
- Volunteers
- 25 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis, ALS
Clinical Trial Ceftriaxone in Subjects With ALS
The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00349622
- Testing
- ceftriaxone
- Where
- 58 sites in United States, Canada
- Volunteers
- 513 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Arimoclomol in Amyotropic Lateral Sclerosis
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
- Trial name
- NCT03491462
- Testing
- Arimoclomol
- Where
- 29 sites in United States, Belgium and 10 more
- Volunteers
- 245 people
- Sponsor
- ZevraDenmark
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in participants with…
- Trial name
- NCT02872142
- Testing
- Albutein 5%, Plasma Exchange
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Grifols Therapeutics LLC
ALS, Amyotrophic Lateral Sclerosis
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety and efficacy of intrathecal treatment delivered to the cerebrospinal fluid (CSF) of mesenchymal stem cells in ALS patients every 3 months for a total of 4 injections over 12…
- Trial name
- NCT03268603
- Testing
- Autologous Adipose-derived Mesenchymal Stromal Cells
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Major Depression, Multiple Sclerosis
Escitalopram (Lexapro) for Depression MS or ALS
The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
- Conditions
- Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT00965497
- Testing
- escitalopram
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of South Carolina